Last updated: July 27, 2026
VISIPAQUE 270 (iodixanol) investment scenario and patent fundamentals analysis
Executive summary: VISIPAQUE 270 (iodixanol) is an established, branded X-ray contrast medium with mature market presence and long-running generic and private-label competition in multiple geographies. From a product-level “patent fundamentals” standpoint, investment impact is driven less by active exclusivity and more by (1) residual brand differentiation in hospital purchasing, (2) supply continuity and manufacturing quality for sterile contrast, (3) payer contracting, and (4) remaining IP around specific concentration presentations, manufacturing process improvements, and label-driven method-of-use claims. Without a verified, current Orange Book-style mapping for the exact drug product strength “270” (and its specific NDC presentations), a complete patent-expiration and litigation risk timeline cannot be produced to support a defensible investment thesis based on exclusivity.
What patents protect VISIPAQUE 270 (iodixanol) and how broad is the patent estate?
Featured snippet (direct answer): Patent protection for iodixanol brands typically clusters around formulation/manufacturing process improvements, packaging and administration-related claims, and method-of-use and labeling claims rather than broad chemical entity coverage, because iodixanol is an old active ingredient with extensive prior art.
What “VISIPAQUE 270” implies for IP scope
- Active ingredient: iodixanol (nonionic, dimeric, water-soluble contrast agent).
- Strength: 270 mg I/mL presentation.
- Likely claim categories that survive around established contrast brands:
- Manufacturing process claims that improve sterility assurance, viscosity control, or particle/impurity profiles.
- Formulation and concentration-specific claims (270 mg I/mL) tied to particular excipient systems, pH targets, osmolarity/viscosity targets, or impurity specifications.
- Container closure or packaging/handling claims (less common but present across sterile injectables).
- Label-related method-of-use claims (often weak for generic entry due to FDA label practice and because generics can rely on carving-out).
- Any remaining improvements that are still within term in certain jurisdictions.
Where investors look for leverage
- Residual exclusivity is not only FDA-data exclusivity. It can come from:
- Patent term remaining in specific countries
- Injunction posture in active disputes
- Sales channel entrenchment that makes “generic switch” slower even when legal exclusivity is expired
Data gap that blocks a complete patent-estate map
A precise “how many patents cover VISIPAQUE 270” count requires:
- exact NDC set for “270” cartons/bottles/vials
- Orange Book listing (if listed for that product) or equivalent national registry linkage
- the set of patents assigned to the exact NDA/ANDA reference used for that product strength
No such mapping is available in the provided information, so an accurate patent inventory and expiration schedule cannot be stated.
When does VISIPAQUE 270 lose exclusivity and when are patent expirations relevant for market entry?
Featured snippet (direct answer): For iodixanol contrast media, exclusivity is generally long expired for the chemical entity, so the relevant question for new competition is whether any late-expiring formulation or process patents (including device/packaging or impurity control) still constrain entry for specific product presentations.
Investment-relevant timeline mechanics
Even for old actives, competition timing can hinge on:
- Patent expirations on concentration-specific presentations (like 270 mg I/mL)
- Launch timing after patent expiry or after litigation settlements
- Regulatory switching cadence in hospital contracts
- Supply chain lead time for cold-chain or container-specific sterilization processes
What to model in an investment case
- Legal calendar: last surviving patents affecting 270 presentation, if any
- Commercial calendar: expected contracting renewal cycles and formulary switch cadence
- Operational calendar: manufacturing validation timeline for sterile contrast products
No expiration dates stated
A defensible exclusivity and patent-expiration schedule cannot be produced without verified, current legal/IP linkage for the exact “VISIPAQUE 270” presentations.
Are there Paragraph IV challenges or biosimilar-style “equivalent” risks for VISIPAQUE 270?
Featured snippet (direct answer): For small-molecule contrast media like iodixanol, “biosimilar-style” risks do not apply. “Paragraph IV” challenges apply to ANDA generic entry in the US when patents are listed in the Orange Book for the reference drug. Whether VISIPAQUE 270 has active or recent Paragraph IV challenges depends on the specific Orange Book patent listings for its exact NDC presentations.
US generic entry risk factors
- If Orange Book patents exist for the specific 270 strength:
- ANDA filers may submit certifications including Paragraph IV (or carve-outs for non-infringed patents).
- If no listed patents remain for that NDC:
- generic entry can occur without an ANDA Paragraph IV dispute.
- For injectable sterile drugs, practical entry friction can be:
- CMC/sterility validation
- impurity profile consistency
- container system equivalence and delivery characteristics
Data gap
An accurate view of Paragraph IV history, active suits, and settlement terms cannot be compiled without the relevant litigation dockets or Orange Book patent list for VISIPAQUE 270 NDCs.
What formulations of iodixanol are protected (270 mg I/mL vs other strengths like 320 mg I/mL) and how does strength matter?
Featured snippet (direct answer): Patent coverage can be concentration-specific. Even with the same active ingredient, formulation/process improvements can be tied to viscosity, osmolarity, pH, and impurity specs that differ by iodixanol strength.
Why concentration matters in IP
- Different strengths can require:
- different target viscosity windows
- different solute mass balancing
- different manufacturing controls to maintain consistent impurity and particle characteristics
- A process patent might explicitly recite parameters that map to one strength.
Investor implication
- If only one strength has residual patent protection:
- switching risk is uneven by hospital ordering pattern.
- distributors may shift volumes to non-protected strengths, impacting revenue.
Data gap
A strength-by-strength protection map for VISIPAQUE 270 cannot be provided without verified patent-to-NDC mapping and claim construction.
How does VISIPAQUE 270 compare with competing iodixanol contrast products on IP and market structure?
Featured snippet (direct answer): Competition in iodixanol contrast media is typically driven by generic and private-label availability, supply reliability, and contracting discounts rather than by a single dominant “remaining exclusivity” barrier.
Comparison dimensions investors should use
- Legal barrier
- remaining patents affecting the exact 270 presentation
- Regulatory equivalence
- ANDA approvals and substitution eligibility
- Supply continuity
- manufacturing capacity, batch release performance, sterility assurance track record
- Commercial access
- group purchasing organization (GPO) placement
- customer conversion rate from brand to generic
- Clinical/label alignment
- any differentiation in indications or administration protocols that affects payer authorization
Data gap
Without a named competitor set for your geography and without VISIPAQUE 270 patent inventory, a credible, cited side-by-side legal and expiry comparison cannot be built.
What is the Orange Book status of VISIPAQUE 270 and what does it imply for generic substitution?
Featured snippet (direct answer): Orange Book status is product- and NDC-specific. If VISIPAQUE 270 has no listed patents currently covering the exact NDC, generic substitution risk is typically higher.
What the Orange Book analysis would determine (once NDCs/patents are known)
- Whether any listed patents are:
- composition of matter
- formulation
- method-of-use
- manufacturing/process
- Whether ANDA filers can qualify without Paragraph IV disputes
- Whether litigation has stayed FDA approval under 21 USC § 355(j)(5)(B) or resolved via settlement
Data gap
Orange Book listing status cannot be stated for “VISIPAQUE 270” without the specific NDC-to-patent listing details.
What patent litigation affects VISIPAQUE 270 and what settlement terms drive future entry?
Featured snippet (direct answer): Contrast media litigation often turns on manufacturing and formulation equivalence for sterile injectable products, with outcomes that can delay generic entry through injunctions or settlements, or accelerate it after stipulations.
Investor checklist
- Identify:
- active or completed Hatch-Waxman cases for the exact NDC/patent list
- whether settlements include:
- date-certain entry schedules
- covenants not to sue
- limitations on product attributes or manufacturing methods
- whether courts issued:
- infringement rulings
- validity rulings (including § 103 obviousness and § 112 issues)
Data gap
No litigation dockets or settlement terms are included in the input, so a complete and accurate litigation section cannot be provided.
FDA regulatory status and approval pathway for VISIPAQUE 270: what does it mean for competition risk?
Featured snippet (direct answer): Once reference drugs have long-standing approval history, competition risk becomes a function of whether the generic route can rely on the reference NDA without triggering patent stays and whether CMC data supports equivalence for the exact strength and container.
Key regulatory risk nodes for injectables
- CMC comparability (particle, impurities, viscosity)
- sterility assurance and container closure
- label and substitution rules in each market
- post-approval change management that can constrain alternate manufacturing
Data gap
The exact FDA approval lineage for VISIPAQUE 270 and current regulatory holders are not supplied; a precise regulatory status cannot be stated.
Commercial fundamentals: how exposed is VISIPAQUE 270 revenue to generic erosion and tender pricing?
Featured snippet (direct answer): For older, off-patent radiographic contrast agents, revenue typically declines toward branded discount levels unless brand procurement contracts and clinical protocols slow switching.
How to model revenue exposure
- Use three levers:
- Generic penetration rate by channel (hospital, outpatient imaging, office-based)
- Tender discount spreads (brand-to-generic price delta)
- Switching elasticity based on:
- formulary status
- physician preference
- supply interruptions and lot-to-lot variability perceptions
Operational fundamentals that matter to investors
- sterile manufacturing reliability and batch release consistency
- global sourcing resilience for raw materials
- pharmacovigilance and complaint rate management
Data gap
No financials, market share, channel mix, or current price levels are provided, so quantified revenue exposure cannot be computed.
Key takeaways
- VISIPAQUE 270 is an established iodixanol contrast medium; investment returns are more sensitive to generic contracting dynamics and manufacturing reliability than to chemical entity exclusivity.
- Patent fundamentals for this product are likely to reside in concentration-specific formulation/process improvements and any remaining US/National listings tied to the exact 270 presentation.
- A complete, decision-grade exclusivity and litigation timeline requires NDC-specific Orange Book mapping and verified court filings; those inputs are not present here.
- In the absence of a verifiable patent/Orange Book inventory, the highest-confidence risk lens is commercial: tender pricing, hospital formulary switching, and supply continuity.
FAQs
- Do generics of iodixanol face Orange Book patent stays for specific concentrations like 270 mg I/mL?
- Can a generic manufacturer enter if patents exist for other iodixanol strengths (e.g., 320 mg I/mL) but not for 270?
- What manufacturing or CMC differences most often drive disputes for sterile contrast injectables?
- How do hospital group purchasing organization (GPO) contracts typically affect branded iodixanol uptake after generic entry?
- What FDA labeling or method-of-use constraints can still limit substitution for radiographic contrast agents?
References
- N/A
